NJ-CARAVAN-BIOLOGIX
15.9.2022 16:01:38 CEST | Business Wire | Press release
Caravan Biologix, Inc., a developer of novel cell-derived vesicle (CDV) therapeutics targeting specific cancers and gene therapy-related diseases, today announced that it has entered into an agreement with Seoul-based MDimune Inc. to apply their nanovesicle technology to enhance the effects of chimeric antigen receptor-expressing natural killer (CAR-NK) cells on various solid tumor cancers. Research findings should provide important insights as Caravan continues to advance the development of its proprietary Mini-CAR™ platform for stand-alone therapeutics and whole-cell CAR co-therapies.
“We are pleased to establish this collaboration with MDimune, a developer of bio-extrusion and delivery,” stated Tom Malcolm, Ph.D., CSO and Founder of Caravan Biologix. “Findings from this collaboration will support our mini-CAR-NK CDV program, which focuses on treating primary liver carcinomas and other human diseases.”
Seung Wook Oh, Ph.D., Chief Scientific Officer of MDimune added, “We are thrilled to launch this collaboration with Caravan Biologix. By joining the advanced mini-CAR-NK technology of Caravan and the enormous therapeutic potential of our vesicle technology, we hope to be able to demonstrate that our BioDrone® platform can significantly escalate the therapeutic promise of current CAR-T/NK-based therapies.”
“The signing of this agreement with Caravan Biologix is another important corporate milestone for MDimune. I am very pleased that our highly innovative and detail-oriented analytical approach to produce the highest quality of cell-derived vesicles at low cost has convinced Caravan Biologix to work with us on such an important endeavor to effectively treat patients with solid tumor cancers. It is clear that new solutions are needed to properly address the complexities associated with traditional whole cell CAR therapeutics,” stated Dr. Oh.
About MDimune Inc.
Founded in 2015, MDimune is dedicated to the development of a next-generation drug delivery platform known as BioDrone®. The company aims to provide a new and flexible modality to generate innovative therapeutics that can address the current challenges of cell & gene therapies. Based on cell-derived vesicles (CDVs) obtained from its proprietary extrusion technology, this novel class of drug carriers will enable highly effective drug delivery to various lesions and allow for treatment with minimum side effects and maximum efficacy. The BioDrone® platform technology is patented in the US, Europe, China, Japan, and Korea. BioDrone® Therapeutics Inc. was founded in 2019 in Seattle, WA to facilitate the global business development of BioDrone® platform technology.
About Caravan Biologix, Inc.
Caravan Biologix is a biotechnology company focused on creating novel therapeutic benefits to broad patient populations by addressing the limitations of whole cell chimeric receptor therapeutics. Caravan’s intellectual property protected technology enables it to develop a wide range of delivery and treatment options from gene editors to small molecules. Our allogeneic iPSC-derived mini-CAR™ and mini-VAN™ platforms, that are based on Cell-Derived Vesicles (CDVs), can be rapidly designed, engineered, and manufactured to build our internal pipeline as well as therapeutics for indications of interest to strategic partners. Caravan’s medicines are expected to show superior safety profiles including lower risk for cytokine release syndrome and other adverse immune reactions. Caravan’s approach will significantly reduce the complexity of manufacturing cell-based therapies, enhance blood-brain barrier penetration properties, and improve the targeted delivery of small molecules and other biologics.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005157/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOYO Corporation Opens Its Quantum Computers to Japan's Ecosystem15.9.2026 10:32:00 CEST | Press release
IQM Spark is TOYO's second quantum computer purchase, following its earlier acquisition of an IQM Radiance 20-qubit quantum computer. IQM will deliver both systems by the end of 2026. Both systems will be operational in early 2027 — the Spark system at TOYO's R&D center, and the Radiance 20 at AIST's Global Research and Development Center for Business by Quantum-AI technology (G-QuAT). TOYO will leverage the quantum infrastructure for its quantum initiatives, while extending access to Japan's wider quantum ecosystem. The move directly supports Japan's national quantum strategy, which targets 10 million domestic quantum users and ¥50 trillion in quantum-generated economic value by 2030. The deployments extend IQM's installed base across Asia-Pacific, following systems already delivered in South Korea and Taiwan. They also follow IQM's Nasdaq listing and an order backlog that has grown past €102 million. IQM Quantum Computers, a global leader in superconducting quantum computers, today a
Smartstream Further Enables Collateral Teams with Instant Answers and Controlled Automation through New MCP Servers15.9.2026 10:00:00 CEST | Press release
Key Facts Smart Collateral helps financial institutions manage the complete margin and collateral lifecycle, providing the control, visibility and governance required to operate at scale. Teams can now interact with that information in plain language, getting answers on agreements, eligibility, positions, margin calls and interest calculations without navigating multiple screens and reports across separate systems. Workflow actions, including creating or failing movements and issuing margin calls, are opt-in, so each firm decides exactly what an AI assistant is permitted to do. Two Model Context Protocol servers connect any MCP-compatible AI assistant to Smart Collateral: one for operating the platform’s APIs, one read-only over the reporting database. Smartstream, the trusted data solutions provider for leading global financial institutions and enterprises, today announces two new Model Context Protocol (MCP) servers for Smart Collateral, enabling dynamic, agentic collateral operation
More Than Half of Global Businesses Want Greater Control Over Their Data in Latest Digital Sovereignty Push, According to Expereo15.9.2026 10:00:00 CEST | Press release
The findings highlight the growing role of network visibility in digital sovereignty strategies as enterprises navigate increasingly complex cloud, AI and connectivity environments Businesses around the world are seeking greater control over their data as growing concerns around AI, security and compliance push digital sovereignty higher up the boardroom agenda, according to the latest IDC InfoBrief commissioned by Expereo*. More than half (53%) of enterprises say they want greater control over sensitive and strategic data, while 33% of global organizations now view digital sovereignty as a top or high priority. The research also found that 30% rank it among the leading drivers of technology investment, highlighting how governance, risk and compliance considerations are becoming increasingly important as organisations scale AI and cloud initiatives. The findings suggest organizations are looking beyond traditional approaches to data governance as they seek to better manage risk, regula
SES and Elveo Mobile Deepen Collaboration to Advance Direct-to-Device Services in Europe15.9.2026 09:30:00 CEST | Press release
SES, a global leader in space solutions, and Elveo Mobile, the company that delivers mobile connectivity and elevated intelligence for a planet on the move, today announced the expansion of their collaboration to accelerate delivery of direct-to-device (D2D) services in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260915183604/en/ SES and Elveo Mobile Deepen Collaboration to Advance Direct-to-Device Services in Europe SES will leverage Elveo’s patented, proven and cost-effective D2D technology to enable seamless mobile roaming capabilities for European consumers, businesses, governments, institutional, and defense users. To further this vision, SES and Elveo Mobile will collaborate to establish manufacturing capabilities and a robust supply chain in Europe for the productions of the Low-Earth Orbit (LEO) D2D satellites, using Elveo’s patented D2D satellite bus, payload and software technology stack. These LEO D2D s
Wolters Kluwer expands Libra legal AI workspace with authoritative expert content from Kluwer Law International15.9.2026 09:01:00 CEST | Press release
Leading arbitration, competition and IP law content now available within Libra by Wolters Kluwer, helping legal professionals access specialist expertise directly in their AI-powered workflows Wolters KluwerLegal & Regulatory today announced the integration of Kluwer Law International content into Libra by Wolters Kluwer, its all-in-one legal AI workspace. Customers in 11 European countries can now access content from Kluwer Arbitration, Kluwer Competition Law and Kluwer IP Law directly within Libra, further expanding the platform's portfolio of trusted legal content and expert insight. The addition of Kluwer Law International content builds on Libra's existing legal intelligence capabilities and gives legal professionals access to specialist international expertise across arbitration, competition law and intellectual property law without leaving their workflow. Content can be used alongside the broader Wolters Kluwer legal resources already available within Libra, helping users conduc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom